Galderma, which is a market dermatology category leader, announced a strong start to 2026, delivering net sales of $1,473 million.
The calculation represents year-on-year net sales growth of 25.5% at constant currency, driven by the strong commercial performance across the the portfolio, with Dermatological Skincare in particular delivering ahead of expectations.
Related: K-Beauty Brand Dr.G Expands to U.S. With Clinically Driven Skincare
Other high-performing product categories included Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%).
Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion.
Galderma is also confirming 2026 full-year guidance, with net sales growth of 17-20% year-on-year at constant currency and a Core EBITDA margin of approximately 26% at constant currency, with increased confidence to navigate a volatile environment.
